Home > Drug Search >
  • Targets: Ribonucleotide reductase (RNR)
  •   > 
Drug Filter
Status:
Approved (66) Withdrawn (2) Phase Ⅱ (11) Phase Ⅰ (5)
Clinical Stage:
Pending (1) Active (7) Discontinued (9)
Company:
Daiichi Sankyo (1) Sumitomo Dainippon (1) Genzyme (1) Gilead (1) GlaxoSmithKline (3) Incyte (1) Janssen (1) Johnson & Johnson (1) Kyowa Hakko Kogyo (1) Lilly (2) Meiji Seika Pharma (1) Merck Sharp & Dohme (1) Mylan (1) Nanotherapeutics (1) National Cancer Institute (1) Novartis (1) Pfizer (6) Roche (1) Sanofi (1) Shionogi (1) Taiho Pharma (1) Us Pharm Holdings (1) Teligent (2) Evolve Oncology (1) Unknown (44) Astex Pharmaceuticals (1) Tolero Pharmaceuticals (1) Wockhardt (1) AmpliMed (1) Titan Pharmaceuticals (1) Novonco Therapeutics (1) Matrix Pharmaceutical (1) Corden (1) Pernix (1) AstraZeneca (1) Basilea Pharmaceutica (1) Bristol-Myers Squibb (3)
Indication:
Acute lymphoblastic leukaemia (ALL) (1) Acute myeloid Leukemia (AML) (2) Advanced breast cancer (1) Advanced ovarian cancer (1) Bladder cancer (1) Breast cancer (1) Chronic myeloid leukemia (CML ) (1) Community-acquired pneumonia (CAP) (1) Complicated intra-abdominal infection (1) Complicated urinary tract infection (1) Lyme disease (2) Herpes simplex virus (1) Essential thrombocythaemia (ET) (1) Gonorrhea (4) Gram-positive and Gram-negative bacterial infections (11) Peritonitis (2) Septicaemia (4) Lung cancer (1) Lymphoma (3) Malignancies (1) Melanoma (1) Multiple myeloma (MM) (1) Myelodysplastic syndrome (MDS) (1) Non small cell lung cancer (NSCLC) (2) Non-Hodgkin’s lymphoma (NHL) (1) Ovarian cancer (2) Paget's disease (1) Pancreatic cancer (1) Pelvic inflammatory disease (2) Pneumonia (2) Prostate cancer (3) Respiratory tract infection (4) Skin infectious (2) Soft tissue infections (1) Solid tumours (5) Urinary tract infections (7) Head and neck cancer (1) Polycythaemia vera (1) Limb girdle muscular dystrophy (1) Colon cancer (1) Complicated skin and skin structure infections (cSSSI) (1) Susceptible bacterial infections (14) Anthrax (1) Otorhinolaryngological infection (1) Prophylaxis of surgical site infection following elective colorectal surgery (1) Intra-abdominal infections (1) Acute gynaecological infections (1) Diabetic foot infections of the skin and soft tissue (1) Urothelial cancer (1) Relapsed or refractory malignant lymphoma (1) Biliary cancer (1) Bacterial Pneumonia (1) Prostatitis (1) Otitis Media (1) Cervical carcinoma (1) Gram-positive bacterial infection (7) Gram-negative bacterial infection (10) Squamous cell carcinoma of head and neck cancer (SCCHN) (1) Staphylococcal infection (2) Bacterial infection (20) Complicated skin and soft tissue infections (2) Skin and soft tissue infections (1) Infectious disease (6) Pseudomonas aeruginosa infection (2)
Country:
JP (2) CA (1) ZA (1)
Aprv. Year:
 (1) 1995 (1) 2005 (1) 2008 (1) 2009 (1)
Others:
Sort: Aprv. Year Alphabetical Prev Next
First Prev 1 2 3 4 Next Last GO
Recently Viewed Drugs:
Insert title here
Feed-Back To Top
ICP Permit 14047345| Beijing PSB Hai Dian Record 11010802017043 |(京)-经营性-2015-0023(互联网药品信息服务资格证书)
Insert title here
Feed-Back To Top